{
  "retracted": false,
  "timestamp": 1480896000000,
  "updates": [
    {
      "timestamp": 1585337756814,
      "identifier": {
        "doi": "10.3310/hta20350-c201611"
      },
      "type": "corrigendum"
    }
  ],
  "identifier": {
    "doi": "10.3310/hta20350"
  },
  "publisher": "National Institute for Health Research",
  "title": "Corrigendum: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation"
}
